Al-Ola A Abdallah: What’s the best approach after M protein reappearance in high-risk Smoldering Myeloma?

Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center, made the following post on X:

“Patient with high-risk Smoldering Myeloma t(4;14) was enrolled in a trial, received aggressive treatment for 2 years, and achieved MRD negativity. After 3 years, M protein reappeared at the same level as when enrolled in the trial, with no evidence of end organ damage.

• Start Dara-RVd/ASCT
• Survillance monthly
• Surveillance Q3 Months
• Start lenalidomide.”

Source: Al-Ola A Abdallah/X